Related stories
Johnson & Johnson to Acquire Ollin Biosciences
Johnson & Johnson will acquire Ollin Biosciences and its late-stage bispecific antibody for ophthalmology.
M impact | EQUITY | Nov 16, 2026, 01:26 PM UTC
Apollo to Invest $2.50 Billion in Focus Financial Partners, Bloomberg Reports
Bloomberg reports that Apollo Global Management is investing $2.50 billion in Focus Financial Partners.
M impact | MNA | Nov 16, 2026, 01:17 PM UTC
JIC Expects More Than ¥900 Billion Gain From JSR Share Sale
Japan Investment Corp. is expected to realize a capital gain of more than ¥900 billion from selling its JSR shares to Mitsui Chemicals.
M impact | MNA | Nov 16, 2026, 01:15 PM UTC
TELUS Board Evaluates Québecor’s Conditional Takeover Proposal
TELUS confirmed that it received an unsolicited, non-binding and conditional proposal from Québecor to acquire the company. TELUS’s Board formed a Special Committee of independent
M impact | MNA | Nov 16, 2026, 01:11 PM UTC
UniCredit Receives Unconditional EU Approval for Commerzbank Acquisition
M impact | MNA | Nov 16, 2026, 01:11 PM UTC
Johnson & Johnson to Buy Ollin Biosciences for at Least $2.20 Billion
M impact | MNA | Nov 16, 2026, 01:06 PM UTC